Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease

ClinicalTrials.gov ID: NCT00889473

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00889473. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 1:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIb, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During a Gluten Challenge

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is designed to evaluate the efficacy of a single dose of larazotide acetate in preventing intestinal permeability changes induced by a 6-week gluten challenge in subjects with celiac disease

Study identification

NCT ID
NCT00889473
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Enrollment
42 participants

Conditions and interventions

Conditions

Interventions

Drug · Dietary Supplement

Eligibility (public fields only)

Age range
18 Years to 72 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 2009 (Actual)
Primary completion
Nov 2009 (Actual)
Completion
Apr 2010 (Actual)
Last update posted
Sep 20, 2017

2009 – 2010

United States locations

U.S. sites
14
U.S. states
10
U.S. cities
14
Facility City State ZIP Site status
Study Site Orange California — —
Study Site Topeka Kansas — —
Study Site Lexington Kentucky — —
Study Site Hagerstown Maryland — —
Study Site Silver Spring Maryland — —
Study Site Chesterfield Michigan — —
Study Site Troy Michigan — —
Study Site Rochester Minnesota — —
Study Site New York New York — —
Study Site Oklahoma City Oklahoma — —
Study Site Paoli Pennsylvania — —
Study Site Philadelphia Pennsylvania — —
Study Site Pittsburgh Pennsylvania — —
Study Site Franklin Tennessee — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00889473, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 20, 2017 · Synced Nov 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.